Investment Recommendations for Zoetis and Energy Transfer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: CNBC
- Zoetis Investment Warning: Zoetis's performance has raised concerns, with analysts expressing a preference for Elanco for the first time, indicating potential challenges for Zoetis in the animal health sector that could impact market confidence and stock performance.
- Energy Transfer Investment Opportunity: Energy Transfer is viewed as a highly attractive investment option, with analysts noting its undervalued stock price and good dividend yield, likely appealing to investors seeking stable income.
- Market Sentiment Shift: The contrasting negative outlook for Zoetis and positive sentiment for Energy Transfer reflects differing expectations in the market, which may lead investors to reassess their portfolios.
- Long-term Investment Strategy: Jim Cramer recommends focusing on Energy Transfer's investment potential, emphasizing its undervalued status and stable dividend yield, which could provide investors with long-term wealth growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 77.820
Low
130.00
Averages
154.20
High
200.00
Current: 77.820
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis to Host Q2 2026 Earnings Call on August 6
- Earnings Call Schedule: Zoetis will host a conference call at 8:30 a.m. (ET) on August 6, 2026, where CEO Kristin Peck and CFO Wetteny Joseph will review Q2 2026 financial results and answer questions from analysts, aiming to enhance investor understanding of the company's financial health.
- Webcast Access: Investors and the public can access the live webcast and corresponding slides on the Zoetis website, with pre-registration available starting today, which is expected to improve company transparency and attract more investor interest.
- Replay Availability: A replay of the conference call will be available on August 6, 2026, ensuring that investors who cannot participate live can still access key information, thereby enhancing communication between the company and its investors.
- Company Background: Zoetis, as the world's leading animal health company, is committed to advancing animal care through innovation and scientific research, serving veterinarians, livestock producers, and pet owners in over 100 countries, showcasing its leadership in the animal health sector.
See More
Zoetis Inc. Shareholder Class Action Notice
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased Zoetis (NYSE: ZTS) shares between January 14, 2025, and May 6, 2026, to contact them for potential lead plaintiff appointment, indicating significant legal risks for the company.
- Declining Market Share: Allegations in the lawsuit claim that Zoetis' products, Librela and Simparica Trio, are experiencing substantial market share losses due to FDA safety warnings and competition from lower-priced alternatives, which could adversely affect future revenues.
- Competitive Pressure: Zoetis' dermatology products, Apoquel and Cytopoint, are also losing market share to newly launched competing treatments, highlighting a weakening competitive position in the pet healthcare market.
- Shareholder Action Advice: Shareholders are advised to register for the class action by July 27, 2026, to receive real-time updates on the case's progress, underscoring the need for improved corporate governance and transparency.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the lawsuit will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Market Share Decline: The lawsuit claims that Zoetis' veterinarian prescription growth and market share for flagship products have significantly weakened due to FDA safety warnings, resulting in investor losses.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
See More
Zoetis Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Zoetis Inc. on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026, alleging that the company made materially false statements and failed to disclose critical business information during this period.
- Market Reaction: Following the release of its first-quarter financial results on May 7, 2026, which revealed a significant decline in its Companion Animal business, Zoetis's stock plummeted by 21.5%, indicating investor concerns regarding the company's future prospects.
- Declining Market Share: The lawsuit highlights that Zoetis's products, including Librela and Simparica Trio, have lost significant market share due to FDA safety warnings and competitive pricing strategies, further impacting the company's financial performance.
- Investor Action: Affected investors must apply for lead plaintiff status by July 27, 2026, to represent other investors in the class action lawsuit, ensuring their legal rights are protected in the proceedings.
See More
Multiple Companies Face Class Action Lawsuits
- AeroVironment Lawsuit: From June 2025 to March 2026, AeroVironment is accused of failing to disclose imminent competition risks, misleading investors about its business prospects, which could negatively impact stock performance.
- Calix Lawsuit: Calix's first-quarter margins were significantly boosted by advanced memory component purchases, yet the company did not inform investors of dwindling supplies, leading to negative margin pressures that could affect future financial health.
- Zoetis Lawsuit: During the period from January 2025 to May 2026, Zoetis failed to disclose that its veterinary prescription growth was sharply declining due to FDA safety warnings, potentially leading to investor misjudgment about its market position and affecting shareholder confidence.
- Lucid Lawsuit: Lucid faced significant delivery disruptions due to supplier quality issues in early 2026, failing to disclose this to investors, which materially impacted its business and financial results, potentially affecting market performance.
See More
Zoetis Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Zoetis is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from January 14, 2025, to May 6, 2026, with a deadline for investor contact set for July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth following FDA safety warnings.
- Declining Market Share: Zoetis's Trio product has lost market share to competitors, while its Apoquel and Cytopoint dermatology products are also losing ground due to the introduction of new competing treatments, exacerbating the company's financial challenges.
- Legal Implications: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act will remain absent class members, potentially forfeiting their ability to recover losses, highlighting the importance of timely participation.
See More
Zoetis to Host Q2 2026 Earnings Call on August 6
- Earnings Call Schedule: Zoetis will host a conference call at 8:30 a.m. (ET) on August 6, 2026, where CEO Kristin Peck and CFO Wetteny Joseph will review Q2 2026 financial results and answer questions from analysts, aiming to enhance investor understanding of the company's financial health.
- Webcast Access: Investors and the public can access the live webcast and corresponding slides on the Zoetis website, with pre-registration available starting today, which is expected to improve company transparency and attract more investor interest.
- Replay Availability: A replay of the conference call will be available on August 6, 2026, ensuring that investors who cannot participate live can still access key information, thereby enhancing communication between the company and its investors.
- Company Background: Zoetis, as the world's leading animal health company, is committed to advancing animal care through innovation and scientific research, serving veterinarians, livestock producers, and pet owners in over 100 countries, showcasing its leadership in the animal health sector.
See More
Zoetis Inc. Shareholder Class Action Notice
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased Zoetis (NYSE: ZTS) shares between January 14, 2025, and May 6, 2026, to contact them for potential lead plaintiff appointment, indicating significant legal risks for the company.
- Declining Market Share: Allegations in the lawsuit claim that Zoetis' products, Librela and Simparica Trio, are experiencing substantial market share losses due to FDA safety warnings and competition from lower-priced alternatives, which could adversely affect future revenues.
- Competitive Pressure: Zoetis' dermatology products, Apoquel and Cytopoint, are also losing market share to newly launched competing treatments, highlighting a weakening competitive position in the pet healthcare market.
- Shareholder Action Advice: Shareholders are advised to register for the class action by July 27, 2026, to receive real-time updates on the case's progress, underscoring the need for improved corporate governance and transparency.
See More
Reminder of Zoetis Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026, to apply as lead plaintiffs by July 27, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the lawsuit will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Market Share Decline: The lawsuit claims that Zoetis' veterinarian prescription growth and market share for flagship products have significantly weakened due to FDA safety warnings, resulting in investor losses.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
See More
Zoetis Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Zoetis Inc. on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026, alleging that the company made materially false statements and failed to disclose critical business information during this period.
- Market Reaction: Following the release of its first-quarter financial results on May 7, 2026, which revealed a significant decline in its Companion Animal business, Zoetis's stock plummeted by 21.5%, indicating investor concerns regarding the company's future prospects.
- Declining Market Share: The lawsuit highlights that Zoetis's products, including Librela and Simparica Trio, have lost significant market share due to FDA safety warnings and competitive pricing strategies, further impacting the company's financial performance.
- Investor Action: Affected investors must apply for lead plaintiff status by July 27, 2026, to represent other investors in the class action lawsuit, ensuring their legal rights are protected in the proceedings.
See More
Multiple Companies Face Class Action Lawsuits
- AeroVironment Lawsuit: From June 2025 to March 2026, AeroVironment is accused of failing to disclose imminent competition risks, misleading investors about its business prospects, which could negatively impact stock performance.
- Calix Lawsuit: Calix's first-quarter margins were significantly boosted by advanced memory component purchases, yet the company did not inform investors of dwindling supplies, leading to negative margin pressures that could affect future financial health.
- Zoetis Lawsuit: During the period from January 2025 to May 2026, Zoetis failed to disclose that its veterinary prescription growth was sharply declining due to FDA safety warnings, potentially leading to investor misjudgment about its market position and affecting shareholder confidence.
- Lucid Lawsuit: Lucid faced significant delivery disruptions due to supplier quality issues in early 2026, failing to disclose this to investors, which materially impacted its business and financial results, potentially affecting market performance.
See More
Zoetis Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Zoetis is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities transactions from January 14, 2025, to May 6, 2026, with a deadline for investor contact set for July 27, 2026.
- Market Misrepresentation: The complaint alleges that Zoetis made false and misleading statements during the class period, leading to investor losses when the truth emerged, particularly as its Librela medication faced declining veterinarian prescription growth following FDA safety warnings.
- Declining Market Share: Zoetis's Trio product has lost market share to competitors, while its Apoquel and Cytopoint dermatology products are also losing ground due to the introduction of new competing treatments, exacerbating the company's financial challenges.
- Legal Implications: Until the class action is certified, investors are not represented by an attorney, and those who choose not to act will remain absent class members, potentially forfeiting their ability to recover losses, highlighting the importance of timely participation.
See More
